Loading clinical trials...
Loading clinical trials...
Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)
Conditions
Interventions
Vilobelimab
Vilobelimab + pembrolizumab combination therapy
Locations
25
United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Anschutz Cancer Pavilion
Aurora, Colorado, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Orlando Health, Inc.
Orlando, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Inova Schar Cancer Institute
Fairfax, Virginia, United States
Start Date
March 31, 2021
Primary Completion Date
June 4, 2024
Completion Date
June 4, 2024
Last Updated
February 11, 2025
Lead Sponsor
InflaRx GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions